Chris sounded more positive than he has in a while. Emphasized how helpful the FDA is being. Talked about NDA first half next year prior to confirmatory study.(he didn't emphasize that 2 days earlier he had said the confimatory study will start 1st quarter next year, but if I heard it correctly, that is what he said 3 days ago.)
The competitor has what sound like obvious dose limiting (and therefore benefit-limiting) toxicities.
SRPT has large platforms if the pmo+ drugs work well as they have done so far with Marburg/ebola.
Huge market for the dmd drug. FDA's Temple sounded almost giddy talking to the ppmd group about potentially using surrogate markers for the smaller-population exons.
A lot of positives.
From one who has watched this company through thick and thin; its time has come.
I bumped this reference up in response to simp's post on possible catalysts coming up soon. If confirmatory study starts 1st quarter next year (pretty soon now) and NDA is going to be filed BEFORE the confirmatory study, NDA will be coming up pretty soon too. The conference this coming week: could part of it be to begin talking about the confirmatory study preliminary-info for parents and kids? all imho